FREMONT, Calif., July 28 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) today announced that its financial results for the
second quarter ended June 30, 2005 will be released following the close of the
U.S. financial markets on Thursday, August 4, 2005. PDL will hold a
conference call to discuss these results, the status of its clinical
development programs, its forward-looking information and guidance with
respect to future results at 4:30 p.m. Eastern time on August 4, 2005. The
call will be hosted by Mr. Mark McDade, Chief Executive Officer, Mr. Glen Y.
Sato, Senior Vice President and Chief Financial Officer, and Dr. Steven
Benner, Senior Vice President and Chief Medical Officer.
The live webcast will be available through the PDL website: http://www.pdl.com.
Please connect to this website at least 15 minutes prior to the live webcast
to allow time for any software download that may be needed to hear the
webcast. Financial and statistical information to be discussed in the call
will be available on the PDL website immediately prior to the commencement of
the call. A replay will be available at http://www.pdl.com starting approximately one
hour after completion of the webcast.
An audio replay will also be available by telephone from approximately
6:30 p.m. Eastern time on August 4, 2005 through 6:30 p.m. Eastern time on
August 12, 2005. To access the replay, dial 800-633-8284 from inside the
United States and 402-977-9140 from outside the United States; enter
conference ID number 21254918.
Protein Design Labs is a biopharmaceutical company focused on the
development and commercialization of novel therapies for treatment of
inflammation and autoimmune diseases, acute cardiac conditions and cancer. As
a leader in the development of humanized antibodies, PDL has licensed its
patents to numerous pharmaceutical and biotechnology companies, some of which
are now paying royalties on net sales of licensed products. PDL markets
several biopharmaceutical products in the United States through its wholly-
owned subsidiary, ESP Pharma, Inc. Further information on PDL is available at
http://www.pdl.com.
NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks
of Protein Design Labs, Inc.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Senior Director, Corporate
Communications, +1-510-248-8851, or aknoefler@pdl.com, or James
R. Goff, Senior Director, Investor Relations, +1-510-574-1421, or
jgoff@pdl.com, both of Protein Design Labs, Inc.
|
